RNS Number : 1500C
Creo Medical Group PLC
26 March 2025
Creo Medical Group plc
("Creo", the "Company" or the "Group")
Grant of Options
Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, announces that on 24 March 2025, it granted options over an aggregate 6,474,713 ordinary shares of £0.001 in the Company (the "Options") to certain Directors of the Company as follows:
Name of Director
Share Options Granted
Exercise Price
Total no. of options over ordinary shares now held
Craig Gulliford
2,062,500
£0.13125
9,970,001
Christopher Hancock
1,384,063
£0.13125
7,832,637
Richard Rees
1,410,938
£0.13125
6,066,870
David Woods
1,617,212
£0.13125
3,712,322
Vesting of the options is subject to performance conditions through to December 2027.
For further information please contact:
Creo Medical Group plc
www.creomedical.com
Richard Craven, Company Secretary
Via Walbrook PR
Deutsche Numis (Nominated Adviser, sole Broker and Financial Adviser) Freddie Barnfield / Duncan Monteith / Euan Brown / Sher Shah
About Creo Medical
Creo is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation, and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less invasive and more cost-efficient option for procedures.
For more information, please refer to the website www.creomedical.com
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Craig Gulliford
2
Reason for the notification
a)
Position/status
Chief Executive Officer
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Creo Medical Group plc
b)
LEI
213800H188ZDCWWXFA21
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Ordinary shares of £0.001 each
Identification code
GB00BZ1BLL44
b)
Nature of the transaction
Grant of Options
c)
Price(s) and volume(s)
Price(s)
Volume(s)
Nil
2,062,500
d)
Aggregated information
- Aggregated volume
N/A - single transaction
- Price
e)
Date of the transaction
24 March 2025
f)
Place of the transaction
Off-market
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Chris Hancock
2
Reason for the notification
a)
Position/status
Chief Technology Officer
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Creo Medical Group plc
b)
LEI
213800H188ZDCWWXFA21
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Ordinary shares of £0.001 each
Identification code
GB00BZ1BLL44
b)
Nature of the transaction
Grant of Options
c)
Price(s) and volume(s)
Price(s)
Volume(s)
Nil
1,384,063
d)
Aggregated information
- Aggregated volume
N/A - single transaction
e)
Date of the transaction
24 March 2025
f)
Place of the transaction
Off-market
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Richard Rees
2
Reason for the notification
a)
Position/status
Chief Financial Officer
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Creo Medical Group plc
b)
LEI
213800H188ZDCWWXFA21
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Ordinary shares of £0.001 each
Identification code
GB00BZ1BLL44
b)
Nature of the transaction
Grant of Options
c)
Price(s) and volume(s)
Price(s)
Volume(s)
Nil
1,410,938
d)
Aggregated information
- Aggregated volume
N/A - single transaction
e)
Date of the transaction
24 March 2025
f)
Place of the transaction
Off-market
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
David Woods
2
Reason for the notification
a)
Position/status
Chief Commercial Officer
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Creo Medical Group plc
b)
LEI
213800H188ZDCWWXFA21
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Ordinary shares of £0.001 each
Identification code
GB00BZ1BLL44
b)
Nature of the transaction
Grant of Options
c)
Price(s) and volume(s)
Price(s)
Volume(s)
Nil
1,617,212
d)
Aggregated information
- Aggregated volume
N/A - single transaction
e)
Date of the transaction
24 March 2025
f)
Place of the transaction
Off market
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHFFFFFVRIEFIE
